Floatz logo

Guanfacine

Self-Injurious Behavior

Maimonides Medical CenterSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Self-Injurious Behavior cohort.

Asset / SponsorPhaseRating
Topamax
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N/AD

Same molecule, other indications

Guanfacine is also rated in:

nervous system disorderDormant
BB
Indicative ·
69 / 100
View asset →
disruptive behavior disorderDormant
BB
Indicative ·
69 / 100
View asset →
Intellectual DisabilityDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →